Navigation Links
AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers

FAIRFAX, Va., Dec. 3 /PRNewswire-USNewswire/ -- Allergy & Asthma Network Mothers of Asthmatics (AANMA) announced today that a new Web-based video geared to help people successfully manage the transition from CFC albuterol inhalers to HFA inhalers is now available at its Web site, Smart Moves to an HFA Inhaler uses technology that allows viewers to ask questions in everyday language and immediately receive a response with relevant, highly focused answers. Users can obtain valuable information about why inhalers are changing, the differences between newer and older inhalers, cost concerns and how to use new HFA inhalers.

"We created this video to help patients and their families learn more about this federal mandate, as a significant number of patients are still not aware of how to safely go about making this change," said Nancy Sander, president and founder of AANMA. "At the end of the year, inhalers are changing. These changes are mandatory, and there are important decisions to make about treatment options that require thoughtful consideration of the patient's medical history and current respiratory health status."

In less than 30 days, life-saving albuterol inhalers used by nearly 40 million patients with respiratory disorders will no longer be sold. After December 31, 2008, it will no longer be permissible to manufacture or sell albuterol inhalers in the United States that contain chlorofluorocarbon (CFC) propellants, because they destroy the Earth's ozone layer. These inhalers have been replaced with four distinct non-CFC propelled alternatives, which contain hydrofluoroalkane (HFA) propellant.

While the transition has been forthcoming for some time, data from IMS Health show that an estimated 14 million CFC prescriptions have yet to be transitioned to HFA MDIs.(1) The absence of a medically responsible transition protocol leaves patients unknowingly exposed to health risks beyond their control.

Patients with asthma, COPD and other respiratory conditions use albuterol at the first sign of symptoms, before exercise and when experiencing breathing exacerbations. Because there are significant differences between CFC and HFA inhalers, patients and medical professionals need to have the opportunity to make the switch in a medically responsible way.

The Web module is hosted by former CNN Medical correspondent Rea Blakey, and supported by an educational grant from Sepracor.

For more information about the MDI transition, please visit AANMA's MDI Transition Web page at Patients seeking information can also call AANMA's Patient Support Center at 800-315-8056.


Founded in 1985, Allergy & Asthma Network Mothers of Asthmatics is the leading national nonprofit family organization dedicated to eliminating suffering and death due to asthma, allergies and related conditions. AANMA's core areas of expertise are education, advocacy and outreach. Call 800.878.4403 or visit

(1) IMS NPA, August 22, 2008

SOURCE Allergy & Asthma Network Mothers of Asthmatics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lucas Group Announces Their Executive Recruitment Military Hiring Conference Schedule for December 2008
2. Axiom Consulting Partners Announces the Results of its Return On Sales Investment Survey
3. United American Healthcare Corporation Announces Stock Repurchase Program
4. eOn Communications Announces GSA Contract
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. USHIFU Announces First Sonablate(R) HIFU Device in India for Minimally Invasive Prostate Cancer Treatment
7. Elsevier announces the 2008 supplement of Reproductive Health Matters
8. Pascal Metrics Announces Patient Safety Culture Services Offering
9. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
10. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
11. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... au traitement photodynamique au Bremachlorin contre le cancer ... approche consistant à combiner l,immunothérapie au traitement photodynamique ... --> Une nouvelle approche consistant ... contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
Breaking Medicine Technology: